Patents by Inventor Tibor Keler

Tibor Keler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Molecular conjugates comprising human monoclonal antibodies to dendritic cells
    Patent number: 7560534
    Abstract: Molecular conjugates comprising an antigen linked to a human monoclonal antibody that specifically binds to dendritic cells are disclosed. Also disclosed are pharmaceutical compositions comprising the molecular conjugates and therapeutic methods for using the conjugates.
    Type: Grant
    Filed: November 7, 2001
    Date of Patent: July 14, 2009
    Assignee: Celldex Research Corporation
    Inventors: Yashwant M. Deo, Tibor Keler, John Treml, Michael Endres
  • ANTIBODIES THAT BIND HUMAN DENDRITIC AND EPITHELIAL CELL 205 (DEC-205)
    Publication number: 20090175880
    Abstract: Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed.
    Type: Application
    Filed: November 7, 2008
    Publication date: July 9, 2009
    Applicant: CELLDEX THERAPEUTICS INC.
    Inventors: Tibor KELER, Lizhen HE, Venky RAMAKRISHNA, Laura A. VITALE
  • Human monoclonal antibodies against protective antigen
    Patent number: 7456264
    Abstract: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: November 25, 2008
    Assignee: Medarex, Inc.
    Inventors: Tibor Keler, Israel Lowy, Laura A. Vitale, Diann Blanset, Mohan Srinivasan
  • Human monoclonal antibodies against CD30
    Patent number: 7387776
    Abstract: Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: June 17, 2008
    Assignee: Medarex, Inc.
    Inventors: Tibor Keler, Robert Graziano, John Treml, Yashwant M. Deo
  • Cells expressing anti-Fc receptor binding components
    Patent number: 7316812
    Abstract: Cells transformed to express on their surface a component which binds to an Fc receptor of an effector cell are disclosed. Also disclosed are expression vectors used to transform the cells. Once transformed, the cells bind to effector cells via the Fc receptor of the effector cell to stimulate an effector cell mediated immune response.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: January 8, 2008
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Robert Graziano, Yashwant M. Deo
  • Human monoclonal antibodies against bacillus anthracis protective antigen
    Publication number: 20050287149
    Abstract: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: May 21, 2004
    Publication date: December 29, 2005
    Applicant: MEDAREX, INC.
    Inventors: Tibor Keler, Israel Lowy, Laura Vitale, Diann Blanset, Mohan Srinivasan
  • Antibody vaccine conjugates and uses therefor
    Publication number: 20050180983
    Abstract: The present invention provides novel antibody vaccine conjugates and methods of using the same to induce a cytotoxic T cell (CTL) response. In a particular, embodiment, the vaccine conjugate includes a human chorionic gonadotropin beta subunit (?hCG) antigen linked to an anti-mannose receptor (MR) antibody.
    Type: Application
    Filed: July 30, 2004
    Publication date: August 18, 2005
    Applicant: CELLDEX Therapeutics, Inc.
    Inventors: Tibor Keler, Michael Endres, Lizhen He, Venky Ramakrishna
  • Cells expressing anti-Fc receptor binding components
    Publication number: 20050142120
    Abstract: Cells transformed to express on their surface a component which binds to an Fc receptor of an effector cell are disclosed. Also disclosed are expression vectors used to transform the cells. Once transformed, the cells bind to effector cells via the Fc receptor of the effector cell to stimulate an effector cell mediated immune response.
    Type: Application
    Filed: January 23, 2004
    Publication date: June 30, 2005
    Inventors: Tibor Keler, Joel Goldstein, Robert Graziano, Yashwant Deo
  • Antibody vaccine conjugates and uses therefor
    Publication number: 20040248215
    Abstract: The present invention provides novel antibody vaccine conjugates and methods of using the same to induce a cytotoxic T cell (CTL) response. In a particular, embodiment, the vaccine conjugate includes a human chorionic gonadotropin beta subunit (&bgr;hCG) antigen linked to an anti-mannose receptor (MR) antibody.
    Type: Application
    Filed: January 30, 2004
    Publication date: December 9, 2004
    Applicant: MEDAREX, INC.
    Inventors: Tibor Keler, Michael Endres, Lizhen He, Venky Ramakrishna
  • Cells expressing anti-Fc receptor binding components
    Patent number: 6682928
    Abstract: Cells transformed to express on their surface a component which binds to an Fc receptor of an effector cell are disclosed. Also disclosed are expression vectors used to transform the cells. Once transformed, the cells bind to effector cells via the Fc receptor of the effector cell to stimulate an effector cell mediated immune response.
    Type: Grant
    Filed: December 2, 1998
    Date of Patent: January 27, 2004
    Assignee: Medarex, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Robert Graziano, Yashwant M. Deo
  • Human monoclonal antibodies against CD30
    Publication number: 20040006215
    Abstract: Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: January 7, 2003
    Publication date: January 8, 2004
    Inventors: Tibor Keler, Robert Graziano, John Treml, Yashwant M. Deo
  • Human monoclonal antibodies to dendritic cells
    Publication number: 20030167502
    Abstract: Isolated human monoclonal antibodies and antigen-binding portions thereof which specifically bind to dendritic cells are disclosed. Also disclosed are bispecifics, immunotoxins and antigen conjugates which include the antibodies or antibody portions. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: May 8, 2001
    Publication date: September 4, 2003
    Inventors: Yashwant M. Deo, Tibor Keler
  • CELLS EXPRESSING ANTI-FC RECEPTOR BINDING COMPONENTS
    Publication number: 20030039641
    Abstract: Cells transformed to express on their surface a component which binds to an Fc receptor of an effector cell are disclosed. Also disclosed are expression vectors used to transform the cells. Once transformed, the cells bind to effector cells via the Fc receptor of the effector cell to stimulate an effector cell mediated immune response.
    Type: Application
    Filed: December 2, 1998
    Publication date: February 27, 2003
    Inventors: TIBOR KELER, JOEL GOLDSTEIN, ROBERT GRAZIANO, YASHWANT M. DEO
  • Human monoclonal antibodies to dendritic cells
    Publication number: 20030031667
    Abstract: Isolated human monoclonal antibodies and antigen-binding portions thereof which specifically bind to dendritic cells are disclosed. Also disclosed are bispecifics, immunotoxins and antigen conjugates which include the antibodies or antibody portions. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: November 7, 2001
    Publication date: February 13, 2003
    Applicant: Medarex, Incorporated
    Inventors: Yashwant M. Deo, Tibor Keler
  • Therapeutic compounds comprised of anti-FC receptor binding agents
    Patent number: 6365161
    Abstract: Multispecific molecules which target immune cells are disclosed. The molecules are “multispecific” because they bind to multiple (two or more), distinct targets, one of which is a molecule on the surface of an immune cell. Multispecific molecules of the invention include molecules comprised of at least one portion which binds to a molecule on an effector cell, such as an Fc receptor, and at least one portion (e.g., two, three, four or more portions) which binds to a different target, such as an antigen on a tumor cell or a pathogen. Multispecific molecules of the invention also include antigen “multimer complexes” comprised of multiple (i.e., two or more) portions which bind to a molecule on an antigen presenting cell (APC), such as an Fc receptor, linked to one or more antigens. These multimer complexes target antigens, such as self-antigens, to APCs to induce and/or enhance internalization (endocytosis), processing and/or presentation of the antigen by the APC.
    Type: Grant
    Filed: July 30, 1999
    Date of Patent: April 2, 2002
    Assignee: Medarex, Inc.
    Inventors: Yashwant M. Deo, Joel Goldstein, Robert Graziano, Tibor Keler
  • Therapeutic multispecific compounds comprised of anti-FCA receptor antibodies
    Patent number: 6303755
    Abstract: Therapeutic multispecific compounds comprised of anti-Fc&agr; receptor antibodies and methods of use are provided.
    Type: Grant
    Filed: March 4, 1999
    Date of Patent: October 16, 2001
    Assignee: Medarex, Inc.
    Inventors: Yashwant M. Deo, Robert Graziano, Tibor Keler
  • Therapeutic multispecific compounds comprised of anti-Fcalpha receptor antibodies
    Publication number: 20010014328
    Abstract: Therapeutic multispecific compounds comprised of anti-Fc&agr; receptor antibodies and methods of use are provided.
    Type: Application
    Filed: January 26, 2001
    Publication date: August 16, 2001
    Applicant: Mederax, Inc.
    Inventors: Yashwant M. Deo, Robert Graziano, Tibor Keler
  • Therapeutic multispecific compounds comprised of anti-Fc&agr; receptor antibodies
    Patent number: 6193966
    Abstract: Therapeutic multispecific compounds comprised of anti-Fc&agr; receptor antibodies and methods of use are provided.
    Type: Grant
    Filed: July 10, 1997
    Date of Patent: February 27, 2001
    Assignee: Mederax, Inc.
    Inventors: Yashwant M. Deo, Robert Graziano, Tibor Keler
  • Therapeutic multispecific compounds comprised of anti-Fc.alpha. receptor antibodies
    Patent number: 5922845
    Abstract: Therapeutic multispecific compounds comprised of anti-Fc.alpha. receptor antibodies and methods of use are provided.
    Type: Grant
    Filed: July 11, 1996
    Date of Patent: July 13, 1999
    Assignee: Medarex, Inc.
    Inventors: Yashwant M. Deo, Robert Graziano, Tibor Keler